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Abstract
Antipsychotic (AP) drugs have the potential to cause prolongation of the QT interval cor-
rected for heart rate (QTc). As this risk is dose-dependent, it may be associated with the
number of AP drugs concurrently prescribed, which is known to be associated with
increased cumulative equivalent AP dosage. This study analysed whether AP dose medi-
ates the relationship between polypharmacy and QTc interval. We used data from a cross-
sectional survey that investigated the prevalence of QTc lengthening among people with
psychiatric illnesses in Italy. AP polypharmacy was tested for evidence of association with
AP dose and QTc interval using the Baron and Kenny mediational model. A total of 725
patients were included in this analysis. Of these, 186 (26%) were treated with two or more
AP drugs (AP polypharmacy). The mean cumulative AP dose was significantly higher in
those receiving AP polypharmacy (prescribed daily dose/defined daily dose = 2.93, stan-
dard deviation 1.31) than monotherapy (prescribed daily dose/defined daily dose = 0.82,
standard deviation 0.77) (z = −12.62, p < 0.001). Similarly, the mean QTc interval was signif-
icantly longer in those receiving AP polypharmacy (mean = 420.86 milliseconds, standard
deviation 27.16) than monotherapy (mean = 413.42 milliseconds, standard deviation 31.54)
(z = −2.70, p = 0.006). The Baron and Kenny mediational analysis showed that, after adjust-
ment for confounding variables, AP dose mediates the association between polypharmacy
and QTc interval. The present study found that AP polypharmacy is associated with QTc
interval, and this effect is mediated by AP dose. Given the high prevalence of AP polyphar-
macy in real-world clinical practice, clinicians should consider not only the myriad risk fac-
tors for QTc prolongation in their patients, but also that adding a second AP drug may
further increase risk as compared with monotherapy.
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Introduction
Antipsychotic (AP) drugs as a group have long been known to have the potential to cause pro-
longation of the QT interval corrected for heart rate (QTc) [1;2]. Data on individual AP drugs
are more controversial, with individual phenothiazines and butyrophenones (e.g., haloperidol)
carrying a higher risk as compared with some individual second-generation AP drugs, such as
quetiapine and olanzapine, which may have a moderate risk, or aripiprazole, possibly showing
a lower potential to cause QTc prolongation [3;4]. However, as many other risk factors for QTc
prolongation have been identified [2;5], these data remain difficult to interpret and somehow
controversial [6].
As the risk is considered dose-dependent [3;7;8], it may also be associated with the number
of AP drugs concurrently prescribed, as AP polypharmacy has consistently been shown to be
associated with increased combined equivalent AP dosage [9;10]. However, a recent systematic
review of 10 clinical trials, 4 observational studies, and 7 case reports, failed to find that AP
polypharmacy worsens QTc interval, although it pointed out that the evidence is scarce and
inconsistent [11]. In a cross-sectional survey carried out to estimate the prevalence of QTc
lengthening in a sample of people with psychiatric illnesses, we showed that AP polypharmacy
was positively associated with QTc prolongation, but the sample of included patients was quite
heterogeneous in terms of cardiovascular disorders and use of medications [4]. Besides,
whether AP dose mediates the association between polypharmacy and QTc interval has not
been investigated yet, largely remaining unknown.
The present study analysed the mediational role of AP dose in the relationship between
polypharmacy and QTc interval. We additionally investigated whether haloperidol and indi-
vidual second-generation AP drugs are associated with QTc prolongation, taking into account
AP polypharmacy and dose.
Materials and Methods
Study Participants
This study is based on data from a cross-sectional survey that investigated the prevalence of
QTc lengthening among people with psychiatric illnesses in Italy [4]. The study was carried out
in 35 Italian psychiatric services that are part of the STAR (Servizi Territoriali Associati per la
Ricerca) Network, a research group established to produce scientific knowledge by collecting
data under ordinary clinical practice. The study design has already been presented elsewhere
[4]. Briefly, during a three-month recruitment period, a consecutive unselected series of both
in- and out- patients were invited to participate. Inpatients aged 18 or above were included if
they gave informed written consent, performed an ECG during hospital stay, and were receiv-
ing pharmacological treatment with psychotropic drugs on the day of ECG recording. For
inpatients with more than one ECG during hospital stay, the first was considered. Outpatients
aged 18 or above were included if they gave informed written consent, underwent ECG exami-
nation during the recruitment period, and were receiving pharmacological treatment with psy-
chotropic drugs on the day of ECG performance. For outpatients with more than one ECG
during the recruitment period, we considered the earliest. A specific psychiatric diagnosis was
not a requirement for inclusion in the study. The study received ethical approval by the Ethics
Committee of the Azienda Ospedaliera Universitaria Integrata, Verona (Approval Number
2409) and by the Ethics Committee of each participating site, and all participants gave their
informed written consent. As all participants had full mental capacity, no specific measure was
adopted to determine capacity to consent.
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Data Collection
Socio-demographic and clinical characteristics were collected from medical records, including
ICD-10 psychiatric diagnosis, alcohol/substances use, recruitment setting, being admitted for
drug overdose, electrolyte (sodium, photassium, calcium, chloride) imbalances, cardiovascular
disorders, drug treatments for psychiatric disorders, drug treatments for other disorders and
antipsychotic prescribed daily doses. Drugs were classified following the Anatomical Thera-
peutic Chemical Classification (ATC) system and, following the Arizona Cert (AzCERT), those
that can cause QTc lengthening under normal clinical usage were identified.
Antipsychotic drug doses (N05A of the ATC group excluding N05AN, lithium) were con-
verted into multiples of the Defined Daily Dose (DDD) for each drug by dividing the pre-
scribed daily dose (PDD) by the DDD [PDD/DDD] [12]. The DDD is the international unit of
drug utilisation approved by the World Health Organisation for drug use studies. It is a theo-
retical unit of measurement defined as the assumed average maintenance daily dose for a drug,
used for its main indication in adults. Expression of drug use in terms of multiples of DDDs
allows calculating, for each patient, a cumulative measure of drug consumption taking into
account the concurrent use of more than one agent. A PDD/DDD ratio of one indicates that
the dose prescribed is equal to the DDD of that drug; a ratio greater than one indicates a dosage
higher than the DDD of that drug, while a ratio lower than one means a dose lower than the
DDD of that drug [13].
The QTc interval estimation was obtained in each participating site from standard 12-lead
ECG. The most common way for interpreting the QT interval is to divide its value by the
square root of the RR interval expressed in seconds, namely, by using Bazett's formula for cor-
rection. The QTc was determined by examining lead II with automatic data acquisition and
was confirmed by a cardiologist who was blind to the patient’s clinical condition.
Sample Definition
For the purposes of this analysis, from the entire sample of recruited patients we excluded
those with risk factors for QTc lengthening (Fig 1). Out of 1776 consecutive patients treated
with AP drugs, we excluded 1051 patients for the following reasons: cardiovascular disorders
and/or cardiovascular drug treatments; electrolyte imbalances when the ECG was performed;
alcohol and/or substance use disorders; drug overdose as reason for admission; use of any
other medicines associated with QTc lengthening according to AzCERT (Fig 1).
Data Analysis
We first tested AP polypharmacy (use of two or more AP drugs) as a dichotomous variable for
evidence of association with socio-demographic information, clinical data and drug use. Chi-
squared statistics were calculated for pairs of dichotomous variables, and Mann-Whitney sta-
tistics were used to analyse continuous variables by AP polypharmacy.
Subsequently, AP polypharmacy was tested for evidence of association with AP dose and
QTc interval in univariate nonparametric test for trend across ordered groups, which is an
extension of the Wilcoxon rank-sum test [14]. As additional step, the Baron and Kenny media-
tional model was applied [15;16]. According to this approach, a mediating role of a variable
exists when four conditions are met: (i) the predictor variable (AP polypharmacy) must be sig-
nificantly related to the outcome variable (QTc interval); (ii) the hypothesized mediator (AP
dose) must be significantly related to the predictor variable (AP polypharmacy); (iii) the medi-
ator (AP dose) must be significantly related to the outcome (QTc interval); and (iv) the rela-
tionship between the predictor (AP polypharmacy) and the outcome (QTc interval) must be
attenuated when controlling for the mediator (AP dose). If the predictor remains significant
AP Polypharmacy and QTc Lengthening
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Fig 1. Flow chart of inclusion and exclusion criteria of cohort of patients treated with antipsychotic drugs.
doi:10.1371/journal.pone.0148212.g001
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when the mediator is controlled for, mediation is deemed to be partial. When controlling for
the mediator renders the predictor non-significant, mediation is deemed complete [15;16]. The
four conditions of the Baron and Kenny mediational model were tested by means of four linear
regression analyses, adjusting for the following confounding variables: sex (female = 1,
male = 0), age (years, continuous variable), psychosis or related disorder (no = 0, yes = 1),
length of illness (years, continuous variable), inpatient status (no = 0, yes = 1), treatment with
AD drugs (no = 0, yes = 1), treatment with mood stabilisers (no = 0, yes = 1). A nonparametric
bootstrap method of statistical accuracy was used, assuming that the observed distribution of
the present sample was a good estimate of the true population distribution [17].
In addition, we tested whether use of haloperidol, risperidone, olanzapine, clozapine, quetia-
pine, paliperidone or aripiprazole was associated with QTc interval. For each of these drugs,
nonparametric bootstrap linear regression analyses were conducted including (i) the con-
founding variables reported above (first analysis), (ii) the confounding variables reported
above plus AP polypharmacy (second analysis), and (iii) the confounding variables reported
above plus AP polypharmacy and AP dose (third analysis). Statistical analysis was carried out
with STATA 13.
Results
Patient Characteristics
A total of 725 patients were included in this analysis (Fig 1). The mean QTc interval was 412.40
ms in men (SD 28.35) and 417.70 ms (SD 32.20) in women. In men, 30 patients (9.23%) showed
a QTc longer than 450 ms, while in women 12 patients (3%) showed a QTc longer than 470 ms.
Of the whole sample, 186 (26%) were treated with two or more AP drugs (AP polypharmacy).
The main socio-demographic and clinical characteristics are presented in Table 1. Patients
receiving AP polypharmacy were more often men, with psychotic disorders, and slightly younger
than patients treated with one AP only. In terms of drug treatments, use of haloperidol, cloza-
pine, quetiapine and aripiprazole was more frequent in patients treated with AP polypharmacy
(Table 1). AD drugs were more often used in those receiving one AP only.
AP Polypharmacy, AP Dose and QTc Interval
The mean AP dose was significantly higher in those receiving AP polypharmacy (PDD/
DDD = 2.93, SD 1.31) than in those receiving AP monotherapy (PDD/DDD = 0.82, SD 0.77)
(z = −12.62, p< 0.001). Similarly, the mean QTc interval was significantly longer in those
receiving AP polypharmacy (mean = 420.86 ms, SD 27.16) than in those receiving AP mono-
therapy (mean = 413.42 ms, SD 31.54) (z = −2.70, p = 0.006). Fig 2 shows that the number of
AP drugs received was significantly associated with AP dose (z test for trend = 12.35,
p< 0.001) and QTc interval (z test for trend = 3.35, p = 0.001).
Fig 3 presents the results of the Baron and Kenny approach. It shows that, after adjustment
for confounding variables, AP polypharmacy was significantly associated with QTc interval
(Model 1); AP polypharmacy was significantly associated with AP dose (Model 2); AP dose
was significantly associated with QTc interval (Model 3); after controlling for AP dose, AP
polypharmacy was no longer associated with QTc interval (Model 4). This suggests that AP
dose mediates the association between polypharmacy and QTc interval.
Individual AP Drug and QTc Interval
We tested whether haloperidol and individual second-generation AP drugs were associated
with QTc lengthening (Table 2), controlling for AP polypharmacy and dose. We failed to find
AP Polypharmacy and QTc Lengthening
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an association between individual AP drugs and QTc interval, but we observed that people on
aripiprazole were significantly less likely to show QTc prolongation, which persisted after con-
trolling for AP dose and polypharmacy (Table 2).
Discussion
The present study found that AP polypharmacy is associated with QTc interval, and this effect
is mediated by AP dose. This finding is noteworthy as clinicians may not be fully aware that
AP polypharmacy is associated with high doses, erroneously arguing that AP polypharmacy
reduces the total amount of AP medication [18]. The risk of QTc lengthening might therefore
be underestimated in patients exposed to two or more concurrent AP drugs.
Table 1. Demographic and clinical features of patients treated with one (monotherapy) or two or more (polypharmacy) antipsychotic (AP) drugs.
AP monotherapy (539) AP polypharmacy (186)
N % N % P-value
Sex men 230 42.67 95 51.08 0.047
women 309 57.33 91 48.92
Age (years) 18–30 95 17.63 27 14.52 0.003
31–50 231 42.86 109 58.60
51–70 183 33.95 42 22.58
71–93 30 5.57 8 4.30
Psychosis no 293 54.36 76 40.86 0.001
yes 246 45.64 110 59.14
Length of illness (years) < 1 53 10.86 11 7.59 0.061
1–5 145 29.71 29 20.00
6–10 79 16.19 28 19.31
11–20 109 22.34 35 24.14
> 20 102 20.90 42 28.97
Inpatients no 173 32.10 47 25.27 0.081
yes 366 67.90 139 74.73
Haloperidol no 454 84.23 105 56.45 0.001
yes 85 15.77 81 43.55
Risperidone no 480 89.05 164 88.17 0.742
yes 59 10.95 22 11.83
Olanzapine no 430 79.78 147 79.03 0.828
yes 109 20.22 39 20.97
Clozapine no 500 92.76 156 83.87 0.001
yes 39 7.24 30 16.13
Quetiapine no 445 82.56 131 70.43 0.001
yes 94 17.44 55 29.57
Paliperidone no 522 96.85 178 95.70 0.460
yes 17 3.15 8 4.30
Aripiprazole no 486 90.17 153 82.26 0.004
yes 53 9.83 33 17.74
Antidepressant drugs no 346 64.19 142 76.34 0.002
yes 193 35.81 44 23.66
Mood Stabilizers no 337 62.52 121 65.05 0.537
yes 202 37.48 65 34.95
doi:10.1371/journal.pone.0148212.t001
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Fig 2. Distribution of antipsychotic dose and QTc interval by number of antipsychotics.
doi:10.1371/journal.pone.0148212.g002
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Risk associated with haloperidol and individual second-generation AP drugs provided addi-
tional clinically interesting insights. First, we failed to detect an increased risk associated with
haloperidol. We argue that this does not suggest a safe profile of haloperidol but, rather, com-
pliance with current safety warnings [19], which may have led to the selection of individuals
without ECG abnormalities. Second, aripiprazole resulted, in comparison with all other AP
drugs, associated with a reduced risk of QTc prolongation. This finding is consistent with the
conclusions of a systematic review that investigated the cardiac safety of aripiprazole treatment
in patients at high risk for torsade [20]. Based on more than 100 preclinical, clinical, and epide-
miological studies, the review found strong evidence in QTc data supporting a safe cardiac pro-
file [20]. In addition, experimental data from placebo and head-to-head comparisons between
Fig 3. Mediational model showing both the direct and the mediated pathways of the relationship
between antipsychotic polypharmacy and QTc interval.Observed coefficients (ß) with standard errors
(SE) and p-values are reported.
doi:10.1371/journal.pone.0148212.g003
Table 2. Relationship between exposure to haloperidol and individual second-generation AP drugs and QTc interval.
Dependent
variable
QTc
Adjusted for Sex, age, length of illness, diagnosis,
setting, AD, MS
Sex, age, length of illness, diagnosis,
setting, AD, MS, number of
antipsychotics
Sex, age, length of illness, diagnosis,
setting, AD, MS, number of
antipsychotics and antipsychotic dose
Drug Coefficient (bias
corrected 95% CI)
z
value
P
value
Coefficient (bias
corrected 95% CI)
z
value
P
value
Coefficient (bias
corrected 95% CI)
z
value
P
value
Haloperidol 3.64 (-2.85 to 10.13) 1.10 0.272 2.27 (-2.57 to 7.12) 0.92 0.358 2.82 (-2.10 to 7.76) 1.12 0.261
Risperidone -2.87 (-10.84 to 5.09) -0.71 0.479 -2.79 (-9.79 to 4.20) -0.78 0.434 -2.08 (-9.74 to 5.57) -0.53 0.593
Olanzapine -0.84 (-5.00 to 3.31) -0.40 0.690 -1.05 (-6.01 to 3.90) -0.42 0.676 -1.86 (-7.15 to 3.42) -0.69 0.490
Clozapine -0.04 (-8.66 to 8.56) -0.01 0.991 -0.88 (-11.50 to 9.74) -0.16 0.871 -0.82 (-10.02 to 8.36) -0.18 0.860
Quetiapine 4.57 (-1.51 to 10.66) 1.47 0.141 3.69 (-2.20 to 9.60) 1.23 0.222 3.92 (-2.34 to 10.20) 1.23 0.220
Paliperidone -2.38 (-11.42 to 6.66) -0.52 0.606 -2.47 (-11.91 to 6.97) -0.51 0.608 0.46 (-8.95 to 8.03) -0.11 0.915
Aripiprazole -10.83 (-19.06 to -2.61) -2.58 0.010 -11.43 (-19.07 to -3.80) -2.94 0.003 -14.00 (-25.10 to -2.91) -2.47 0.013
CI = Confidence interval; AD = antidepressants; MS = mood stabilisers
doi:10.1371/journal.pone.0148212.t002
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different AP drugs found that aripiprazole was not associated with significant QTc prolonga-
tion compared with placebo, and that it was the second best choice in terms of risk of ECG
abnormalities second only to lurasidone [21].
These findings should be interpreted bearing in mind some study limitations. A first con-
cern refers to the possibility of confounding, as there are several risk factors for QTc prolonga-
tion [2;5]. In this analysis, instead of statistically controlling for some of these risk factors, we
restricted the analysis to patients without some characteristics that are known to be associated
with QTc lengthening, including cardiovascular disorders and a number of medications.
Although this has indubitably increased homogeneity of the study sample, we acknowledge
that we were not able to take into consideration other potential contributing factors, such as
obesity, malnutrition or hepatic dysfunctions. For example, recent data have shown that AP
drugs may be associated with non-alcoholic fatty liver disease (NAFLD) [22], and NAFLD has
been shown to increase the risk of a wide spectrum of cardiovascular and cardiac abnormalities,
including increased QTc interval [23]. Therefore, AP drugs, in addition to direct cardiac toxic-
ity, may be conducive to increased QTc interval via dysmetabolism and NAFLD. Another limi-
tation relates to the small numbers of patients taking some individual drugs, resulting in both
limited statistical power to detect associations with QTc interval and unfeasibility to test associ-
ations between QTc prolongation and some “classical” AP combinations (e.g. those involving
aripiprazole or clozapine) recommended by evidence-based guidelines [24]. Last, the choice of
using ECG data collected for clinical purposes, which may have introduced some heterogeneity
in terms of different centres measuring the QT interval in slightly different ways, was motivated
by an attempt to resemble as much as possible clinical practice.
Given the high prevalence of AP polypharmacy in real-world clinical practice, still in
absence of solid evidence, this study has several implications for routine treatment pro-
grammes. Clinicians should bear in mind that since AP polypharmacy is not associated with
reduced cumulative dose of AP drugs [25], but the combined equivalent is significantly higher
in those receiving AP polypharmacy compared with those on monotherapy, this may actually
worsen the QTc interval. Guidelines for the use of AP polypharmacy are progressively moving
from recommending it only in patients with clozapine-refractory psychosis [26] towards a
more extensive use [27]. Thus, clinicians should consider not only the myriad risk factors for
QTc prolongation in their patients, but also that adding a second AP drug may further increase
risk as compared with monotherapy. In patients exposed to AP polypharmacy, it may be pru-
dent to monitor QTc before treatment, and then regularly during treatment, depending on the
estimated risk.
Clinicians should also consider that AP polypharmacy is not unalterable. Switching from
polypharmacy to monotherapy has been shown to be feasible in a majority of patients with
schizophrenia, and assertive educational interventions, rather than educational approaches
alone, were found to be effective supportive strategies in reducing AP polypharmacy [28].
In terms of implications for research, these data suggest that controlled, high-quality AP
combination trials are necessary to determine the effectiveness, safety, and role of AP polyphar-
macy in the management of severely ill patients. Among safety outcomes, studies should always
include measures of cardiac functioning, including the QTc interval.
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